# ANI Pharmaceuticals Inc: financial statements, quarterly

ANIP · Nasdaq · CIK 1023024 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/anip.md) · [Financials](/companies/anip/financials.md) · [Filings](/companies/anip/filings.md) · [Insiders](/companies/anip/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/anip/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [132](/filings/0001023024-24-000102.md) | [132 d](/filings/0001023024-26-000014.md) | [137](/filings/0001023024-25-000046.md) | [138](/filings/0001023024-25-000082.md) | [148](/filings/0001023024-25-000108.md) | [191 d](/filings/0001023024-26-000014.md) | [197](/filings/0001023024-26-000050.md) | [211](/filings/0001023024-26-000069.md) | [228](/filings/0001023024-25-000108.md) | [247 d](/filings/0001023024-26-000014.md) | [237](/filings/0001023024-26-000050.md) | [266](/filings/0001023024-26-000069.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [11.1](/filings/0001023024-24-000102.md) | [9.9 d](/filings/0001023024-26-000014.md) | [10.5](/filings/0001023024-25-000046.md) | [7.3](/filings/0001023024-25-000082.md) | [10.1](/filings/0001023024-25-000108.md) | [16.6 d](/filings/0001023024-26-000014.md) | [10.6](/filings/0001023024-26-000050.md) | [16.5](/filings/0001023024-26-000069.md) | [12.3](/filings/0001023024-25-000108.md) | [12.3 d](/filings/0001023024-26-000014.md) | [10.6](/filings/0001023024-26-000050.md) | [14.7](/filings/0001023024-26-000069.md) |
| Selling, general and administrative | $m | [42.0](/filings/0001023024-24-000102.md) | [44.5 d](/filings/0001023024-26-000014.md) | [48.0](/filings/0001023024-25-000046.md) | [52.8](/filings/0001023024-25-000082.md) | [79.1](/filings/0001023024-25-000108.md) | [69.7 d](/filings/0001023024-26-000014.md) | [76.5](/filings/0001023024-26-000050.md) | [81.8](/filings/0001023024-26-000069.md) | [76.7](/filings/0001023024-25-000108.md) | [82.8 d](/filings/0001023024-26-000014.md) | [73.7](/filings/0001023024-26-000050.md) | [91.7](/filings/0001023024-26-000069.md) |
| Operating income | $m | [17.9](/filings/0001023024-24-000102.md) | [6.7 d](/filings/0001023024-26-000014.md) | [20.3](/filings/0001023024-25-000046.md) | [5.2](/filings/0001023024-25-000082.md) | [(20.5)](/filings/0001023024-25-000108.md) | [(4.4) d](/filings/0001023024-26-000014.md) | [26.2](/filings/0001023024-26-000050.md) | [13.9](/filings/0001023024-26-000069.md) | [36.2](/filings/0001023024-25-000108.md) | [34.8 d](/filings/0001023024-26-000014.md) | [38.9](/filings/0001023024-26-000050.md) | [40.5](/filings/0001023024-26-000069.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [1.6](/filings/0001023024-24-000102.md) | [(0.2) d](/filings/0001023024-26-000014.md) | [7.1](/filings/0001023024-25-000046.md) | [0.0](/filings/0001023024-25-000082.md) | [(7.3)](/filings/0001023024-25-000108.md) | [(3.5) d](/filings/0001023024-26-000014.md) | [4.3](/filings/0001023024-26-000050.md) | [2.0](/filings/0001023024-26-000069.md) | [7.2](/filings/0001023024-25-000108.md) | [4.0 d](/filings/0001023024-26-000014.md) | [10.7](/filings/0001023024-26-000050.md) | [12.4](/filings/0001023024-26-000069.md) |
| Net income | $m | [9.9](/filings/0001023024-24-000102.md) | [1.2 d](/filings/0001023024-26-000014.md) | [18.2](/filings/0001023024-25-000046.md) | [(2.3)](/filings/0001023024-25-000082.md) | [(24.2)](/filings/0001023024-25-000108.md) | [(10.3) d](/filings/0001023024-26-000014.md) | [15.7](/filings/0001023024-26-000050.md) | [8.5](/filings/0001023024-26-000069.md) | [26.6](/filings/0001023024-25-000108.md) | [27.5 d](/filings/0001023024-26-000014.md) | [29.5](/filings/0001023024-26-000050.md) | [24.7](/filings/0001023024-26-000069.md) |
| Diluted EPS | $ per share | [0.45](/filings/0001023024-24-000102.md) | not reported | [0.82](/filings/0001023024-25-000046.md) | [(0.14)](/filings/0001023024-25-000082.md) | [(1.27)](/filings/0001023024-25-000108.md) | not reported | [0.69](/filings/0001023024-26-000050.md) | [0.36](/filings/0001023024-26-000069.md) | [1.13](/filings/0001023024-25-000108.md) | not reported | [1.28](/filings/0001023024-26-000050.md) | [1.05](/filings/0001023024-26-000069.md) |
| Basic EPS | $ per share | [0.46](/filings/0001023024-24-000102.md) | not reported | [0.84](/filings/0001023024-25-000046.md) | [(0.14)](/filings/0001023024-25-000082.md) | [(1.27)](/filings/0001023024-25-000108.md) | not reported | [0.70](/filings/0001023024-26-000050.md) | [0.37](/filings/0001023024-26-000069.md) | [1.19](/filings/0001023024-25-000108.md) | not reported | [1.31](/filings/0001023024-26-000050.md) | [1.09](/filings/0001023024-26-000069.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [193](/filings/0001023024-23-000043.md) | [221](/filings/0001023024-26-000014.md) | [229](/filings/0001023024-24-000057.md) | [240](/filings/0001023024-24-000085.md) | [145](/filings/0001023024-25-000108.md) | [145](/filings/0001023024-26-000069.md) | [150](/filings/0001023024-26-000050.md) | [218](/filings/0001023024-26-000069.md) | [263](/filings/0001023024-25-000108.md) | [286](/filings/0001023024-26-000069.md) | [311](/filings/0001023024-26-000050.md) | [360](/filings/0001023024-26-000069.md) |
| Current assets | $m | [497](/filings/0001023024-23-000043.md) | [520](/filings/0001023024-25-000015.md) | [541](/filings/0001023024-24-000057.md) | [555](/filings/0001023024-24-000085.md) | [521](/filings/0001023024-24-000102.md) | [528](/filings/0001023024-26-000014.md) | [536](/filings/0001023024-25-000046.md) | [603](/filings/0001023024-25-000082.md) | [698](/filings/0001023024-25-000108.md) | [753](/filings/0001023024-26-000069.md) | [747](/filings/0001023024-26-000050.md) | [825](/filings/0001023024-26-000069.md) |
| Total assets | $m | [890](/filings/0001023024-23-000043.md) | [904](/filings/0001023024-25-000015.md) | [915](/filings/0001023024-24-000057.md) | [921](/filings/0001023024-24-000085.md) | [1,287](/filings/0001023024-24-000102.md) | [1,284](/filings/0001023024-26-000014.md) | [1,292](/filings/0001023024-25-000046.md) | [1,343](/filings/0001023024-25-000082.md) | [1,408](/filings/0001023024-25-000108.md) | [1,440](/filings/0001023024-26-000069.md) | [1,422](/filings/0001023024-26-000050.md) | [1,494](/filings/0001023024-26-000069.md) |
| Current liabilities | $m | [134](/filings/0001023024-23-000043.md) | [145](/filings/0001023024-25-000015.md) | [137](/filings/0001023024-24-000057.md) | [140](/filings/0001023024-24-000085.md) | [190](/filings/0001023024-24-000102.md) | [194](/filings/0001023024-26-000014.md) | [202](/filings/0001023024-25-000046.md) | [237](/filings/0001023024-25-000082.md) | [271](/filings/0001023024-25-000108.md) | [278](/filings/0001023024-26-000069.md) | [240](/filings/0001023024-26-000050.md) | [284](/filings/0001023024-26-000069.md) |
| Total liabilities | $m | [435](/filings/0001023024-23-000043.md) | [447](/filings/0001023024-25-000015.md) | [438](/filings/0001023024-24-000057.md) | [440](/filings/0001023024-24-000085.md) | [857](/filings/0001023024-24-000102.md) | [856](/filings/0001023024-26-000014.md) | [849](/filings/0001023024-25-000046.md) | [881](/filings/0001023024-25-000082.md) | [902](/filings/0001023024-25-000108.md) | [900](/filings/0001023024-26-000069.md) | [860](/filings/0001023024-26-000050.md) | [897](/filings/0001023024-26-000069.md) |
| Long-term debt | $m | [285](/filings/0001023024-23-000043.md) | [285](/filings/0001023024-25-000015.md) | [285](/filings/0001023024-24-000057.md) | [284](/filings/0001023024-24-000085.md) | [313](/filings/0001023024-24-000102.md) | [309](/filings/0001023024-26-000014.md) | [305](/filings/0001023024-25-000046.md) | [301](/filings/0001023024-25-000082.md) | [298](/filings/0001023024-25-000108.md) | [292](/filings/0001023024-26-000069.md) | [286](/filings/0001023024-26-000050.md) | [280](/filings/0001023024-26-000069.md) |
| Current portion of debt | $m | [0.9](/filings/0001023024-23-000043.md) | [0.9](/filings/0001023024-25-000015.md) | [0.9](/filings/0001023024-24-000057.md) | [0.9](/filings/0001023024-24-000085.md) | [7.2](/filings/0001023024-24-000102.md) | [9.2](/filings/0001023024-26-000014.md) | [11.2](/filings/0001023024-25-000046.md) | [13.2](/filings/0001023024-25-000082.md) | [15.2](/filings/0001023024-25-000108.md) | [17.3](/filings/0001023024-26-000069.md) | [19.3](/filings/0001023024-26-000050.md) | [21.3](/filings/0001023024-26-000069.md) |
| Shareholders' equity | $m | [430](/filings/0001023024-23-000043.md) | [433](/filings/0001023024-25-000015.md) | [452](/filings/0001023024-24-000057.md) | [456](/filings/0001023024-24-000085.md) | [406](/filings/0001023024-24-000102.md) | [404](/filings/0001023024-26-000014.md) | [419](/filings/0001023024-25-000046.md) | [437](/filings/0001023024-25-000082.md) | [506](/filings/0001023024-25-000108.md) | [541](/filings/0001023024-26-000069.md) | [562](/filings/0001023024-26-000050.md) | [597](/filings/0001023024-26-000069.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [32.2 d](/filings/0001023024-24-000102.md) | [44.7 d](/filings/0001023024-26-000014.md) | [18.3](/filings/0001023024-25-000046.md) | [17.4 d](/filings/0001023024-25-000082.md) | [12.5 d](/filings/0001023024-25-000108.md) | [15.9 d](/filings/0001023024-26-000014.md) | [35.0](/filings/0001023024-26-000050.md) | [75.8 d](/filings/0001023024-26-000069.md) | [44.1 d](/filings/0001023024-25-000108.md) | [30.4 d](/filings/0001023024-26-000014.md) | [58.4](/filings/0001023024-26-000050.md) | [56.7 d](/filings/0001023024-26-000069.md) |
| Capital expenditure | $m | [1.7 d](/filings/0001023024-24-000102.md) | [2.3 d](/filings/0001023024-26-000014.md) | [4.6](/filings/0001023024-25-000046.md) | [4.4 d](/filings/0001023024-25-000082.md) | [4.8 d](/filings/0001023024-25-000108.md) | [2.4 d](/filings/0001023024-26-000014.md) | [2.5](/filings/0001023024-26-000050.md) | [4.0 d](/filings/0001023024-26-000069.md) | [6.1 d](/filings/0001023024-25-000108.md) | [1.2 d](/filings/0001023024-26-000014.md) | [6.1](/filings/0001023024-26-000050.md) | [3.1 d](/filings/0001023024-26-000069.md) |
| Dividends paid | $m | [0.4 d](/filings/0001023024-24-000102.md) | [0.4 d](/filings/0001023024-26-000014.md) | [0.4](/filings/0001023024-25-000046.md) | [0.4 d](/filings/0001023024-25-000082.md) | [0.4 d](/filings/0001023024-25-000108.md) | [0.4 d](/filings/0001023024-26-000014.md) | [0.4](/filings/0001023024-26-000050.md) | [0.4 d](/filings/0001023024-26-000069.md) | [0.3 d](/filings/0001023024-25-000108.md) | [0.0 d](/filings/0001023024-26-000014.md) | [0.0](/filings/0001023024-26-000050.md) | [0.0 d](/filings/0001023024-26-000069.md) |
| Share repurchases | $m | [0.7 d](/filings/0001023024-24-000102.md) | [0.2 d](/filings/0001023024-26-000014.md) | [8.7](/filings/0001023024-25-000046.md) | [1.3 d](/filings/0001023024-25-000082.md) | [0.7 d](/filings/0001023024-25-000108.md) | [0.3 d](/filings/0001023024-26-000014.md) | [10.0](/filings/0001023024-26-000050.md) | [0.6 d](/filings/0001023024-26-000069.md) | [1.0 d](/filings/0001023024-25-000108.md) | [0.6 d](/filings/0001023024-26-000014.md) | [19.8](/filings/0001023024-26-000050.md) | [0.8 d](/filings/0001023024-26-000069.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [16.3](/filings/0001023024-23-000043.md) | [16.5](/filings/0001023024-24-000057.md) | [17.9](/filings/0001023024-24-000085.md) | [19.1](/filings/0001023024-24-000102.md) | [19.4](/filings/0001023024-25-000046.md) | [19.3](/filings/0001023024-25-000082.md) | [19.4](/filings/0001023024-25-000108.md) | [20.0](/filings/0001023024-26-000050.md) | [20.3](/filings/0001023024-26-000069.md) | [21.1](/filings/0001023024-25-000108.md) | [21.5](/filings/0001023024-26-000050.md) | [21.9](/filings/0001023024-26-000069.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 24,422,240 at 2013-02-28, from the cover of the [10-K filed 2013-02-28](/filings/0001104659-13-016148.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:30 ET. No prices; not investment advice.